The purity indicated in this column was the minimum degree of purity of the active substance evaluated. The active substance in the product placed on the market can be of equal or different purity if it has been proven to be technically equivalent to the evaluated active substance.    ,

Azoxystrobin,  IUPAC Name:    Methyl(E)-2-{2[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate    EC No: not available    CAS No: 131860-33-8  ,965 g/kg,1 November 2018,31 October 2025,7,  Azoxystrobin is considered a candidate for substitution in accordance with point (d) of Article 10(1) of Regulation (EU) No 528/2012.    The authorisations of biocidal products are subject to the following condition:    The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance.    The placing on the market of treated articles is subject to the following condition:    The person responsible for the placing on the market of a treated article treated with or incorporating azoxystrobin shall ensure that the label of that treated article provides the information listed in the second subparagraph of Article 58(3) of Regulation (EU) No 528/2012.  ,
9,  Azoxystrobin is considered a candidate for substitution in accordance with point (d) of Article 10(1) of Regulation (EU) No 528/2012.    The authorisations of biocidal products are subject to the following condition:    The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance.    The placing on the market of treated articles is subject to the following condition:    The person responsible for the placing on the market of a treated article treated with or incorporating azoxystrobin shall ensure that the label of that treated article provides the information listed in the second subparagraph of Article 58(3) of Regulation (EU) No 528/2012.  ,
10,  Azoxystrobin is considered a candidate for substitution in accordance with Article 10(1)(d) of Regulation (EU) No 528/2012.    The authorisations of biocidal products are subject to the following condition:    The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance.    The placing on the market of treated articles is subject to the following condition:    The person responsible for the placing on the market of a treated article treated with or incorporating azoxystrobin shall ensure that the label of that treated article provides the information listed in the second subparagraph of Article 58(3) of Regulation (EU) No 528/2012.  ,